Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Final Guidance Encourages Use Of Patient Preference In Device Applications

Executive Summary

US FDA released a final guidance aimed at helping sponsors and other stakeholders interested in using patient-preference information to make their case for a device application. The agency has decided to keep its labeling recommendation in the final guidance despite industry objections.

You may also be interested in...



Preferential Treatment: US FDA Asks Patients For Their Input

As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.

Shuren: New Uncertainty Draft Guidance Looks Beyond p-Values

After years of talking about how to tackle uncertainty of benefit/risk in devices under review, US FDA has released a guidance on the issue. Medtech Insight caught up with FDA device center director Jeff Shuren at a meeting in Washington, DC, to talk about the guidance and what he hopes will come of it.

US FDA Tackles HDE 'Probable Benefits' Question In Draft Guidance

In accordance with the 21st Century Cures Act, FDA has published a draft guidance on how it will assess devices intended for orphan diseases under the humanitarian device exemption pathway. A key part of the guidance attempts to address the agencies thinking on what is considered probable benefit.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel